Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 1;20(3):1036-1038.
doi: 10.4103/jcrt.jcrt_739_22. Epub 2023 Apr 6.

Intrapleural nivolumab in cancer patients with pleural effusion

Ilya Tsimafeyeu  1 , Vadim Goutnik  2 , Igor Shrainer  3   4 , Vladislav Kosyrev  5 , Anastasia Bondarenko  6 , Igor Utyashev  5
Affiliations
Free article

Intrapleural nivolumab in cancer patients with pleural effusion

Ilya Tsimafeyeu et al. J Cancer Res Ther. .
Free article

Abstract

We assessed the preliminary efficacy and toxicity of intrapleural instillation of nivolumab in patients with large pleural effusion. Patients with metastatic cancers who have a large volume of pleural effusion and required evacuation were eligible. Thoracentesis followed by nivolumab (40 mg, single intrapleural instillation) was performed. The primary endpoint was 3-month recurrence-free survival. A total of 13 patients were enrolled. The study was terminated after stage 1 as no efficacy was observed; 7 patients (54%) had a recurrence of pleural effusion at 3 months. Thirteen (100%) patients had no recurrence, dyspnea, or cough within 1 month, and the median time to recurrence was 1.9 months (95% confidence interval [CI], 1.35-2.5). No adverse events were identified. We concluded that a single intrapleural instillation of the nivolumab at 40 mg was ineffective and well-tolerated in cancer patients with pleural effusion.

PubMed Disclaimer

References

    1. Skok K, Hladnik G, Grm A, Crnjac A. Malignant pleural effusion and its current management:A review. Medicina (Kaunas) 2019;55:490.
    1. Deng H-Y, Li D, Ren Y, Wang K, Tang X. Targeted therapy followed by salvage surgery and adjuvant therapy:A promising therapy for lung cancer with malignant pleural effusion from a case report. Front Surg 2021;8:659983.
    1. Rodrîguez-Panadero F, Borderas Naranjo F, López Mejîas J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989;2:366–9.
    1. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion:British thoracic society pleural disease guideline 2010. Thorax 2010;65 (Suppl 2):ii32–40.
    1. Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med 2018;198:839.

MeSH terms

Substances

LinkOut - more resources